Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Website: unicycive.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 0% of quarters (showing a gain of -$0.18 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 90.3% (LTM)

Entry Point: Share price is 134.1% higher than minimum and 82.4% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: UNCY
Share price, USD:  (+6.2%)1.03
year average price 1.0465  


year start price 1.2600 2023-05-01

min close price 0.4900 2023-12-01

max close price 1.7900 2024-02-23

current price 1.0300 2024-04-29
Common stocks: 15 057 049

Dividend Yield:  0.0%
Last revenue growth (y/y):  0.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  ---
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 16
Net Debt ($m): -13
EV (Enterprise Value): 3
Price to Book: -4.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-10GlobeNewsWire

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

2024-02-14GlobeNewsWire

Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting

2024-01-24Zacks Investment Research

Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update

2023-11-29GlobeNewsWire

Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023

2023-06-30InvestorPlace

Why Is Unicycive Therapeutics (UNCY) Down 24% Today?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol UNCY UNCY UNCY UNCY UNCY UNCY UNCY
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-28 2023-11-14 2023-08-14 2023-05-16 2023-03-31 2022-11-14 2022-08-15
acceptedDate 2024-03-28 16:06:15 2023-11-14 16:20:39 2023-08-14 17:12:17 2023-05-16 08:56:17 2023-03-30 21:24:20 2022-11-14 07:10:23 2022-08-15 17:56:51
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 0 675 000 0 951 000 0
costOfRevenue 82 000 79 000 78 000 0 0 0 0
grossProfit -82 000 -79 000 -78 000 675 000 0 951 000 0
grossProfitRatio 0 0 0 1.000 0 1.000 0
researchAndDevelopmentExpenses 4M 3M 2M 3M 4M 5M 2M
generalAndAdministrativeExpenses 2M 3M 2M 2M 1M 2M 2M
sellingAndMarketingExpenses -82 000 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 2M 3M 2M 2M 1M 2M 2M
otherExpenses 0 0 0 0 0 0 0
operatingExpenses 6M 6M 4M 5M 5M 7M 4M
costAndExpenses 6M 6M 4M 5M 5M 7M 0
interestIncome 140 000 227 000 234 000 14 000 0 0 0
interestExpense 19 000 -18 000 32 000 12 000 3000.000 3000.000 0
depreciationAndAmortization 82 000 79 000 78 000 59 000 42 000 40 000 40 000
ebitda -6M -6M -4M -4M -5M -6M -4M
ebitdaratio 0 0 0 -6.138 0 -5.798 0
operatingIncome -6M -6M -4M -4M -5M -6M -4M
operatingIncomeRatio 0 0 0 -6.225 0 -5.840 0
totalOtherIncomeExpensesNet -1M 2M 282 000 -10M -3000.000 -3000.000 0
incomeBeforeTax -8M -4M -4M -15M -5M -6M -4M
incomeBeforeTaxRatio 0 0 0 -21.593 0 -5.843 0
incomeTaxExpense 0 -79 000 32 000 11M 3000.000 3000.000 0
netIncome -8M -4M -4M -25M -5M -6M -4M
netIncomeRatio 0 0 0 -37.262 0 -5.846 0
eps -0.220 -0.130 -0.250 -1.650 -0.350 -0.370 -0.240
epsdiluted -0.220 -0.130 -0.250 -1.650 -0.350 -0.370 -0.240
weightedAverageShsOut 35M 33M 15M 15M 15M 15M 15M
weightedAverageShsOutDil 35M 33M 15M 15M 15M 15M 15M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol UNCY UNCY UNCY UNCY UNCY UNCY UNCY
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-28 2023-11-14 2023-08-14 2023-05-16 2023-03-31 2022-11-14 2022-08-15
acceptedDate 2024-03-28 16:06:15 2023-11-14 16:20:39 2023-08-14 17:12:17 2023-05-16 08:56:17 2023-03-30 21:24:20 2022-11-14 07:10:23 2022-08-15 17:56:51
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 10M 14M 19M 24M 455 000 7M 11M
shortTermInvestments 0 0 0 0 0 0 0
cashAndShortTermInvestments 10M 14M 19M 24M 455 000 7M 11M
netReceivables 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0
otherCurrentAssets 4M 682 000 320 000 319 000 159 000 69 000 2M
totalCurrentAssets 13M 19M 22M 26M 3M 10M 13M
propertyPlantEquipmentNet 792 000 873 000 953 000 1M 174 000 215 000 256 000
goodwill 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0
otherNonCurrentAssets 0 0 -953 000 0 0 0 0
totalNonCurrentAssets 792 000 873 000 953 000 1M 174 000 215 000 256 000
otherAssets 0 0 0 0 0 0 0
totalAssets 14M 19M 23M 27M 3M 10M 13M
accountPayables 821 000 990 000 446 000 610 000 846 000 2M 747 000
shortTermDebt 345 000 314 000 303 000 276 000 201 000 165 000 160 000
taxPayables 0 0 0 0 0 0 0
deferredRevenue 1.000 3M 2M 0 0 0 0
otherCurrentLiabilities 16M 12M 13M 15M 2M 3M 2M
totalCurrentLiabilities 18M 15M 15M 16M 3M 6M 3M
longTermDebt 466 000 552 000 634 000 715 000 0 29 000 72 000
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 1M -2M 0
totalNonCurrentLiabilities 466 000 552 000 634 000 715 000 1M 29 000 72 000
otherLiabilities 0 0 0 0 -1M 0 0
capitalLeaseObligations 466 000 866 000 937 000 991 000 155 000 194 000 232 000
totalLiabilities 18M 16M 16M 17M 3M 6M 3M
preferredStock 0 44 000 26M 26M 0 0 0
commonStock 35 000 35 000 15 000 15 000 15 000 15 000 15 000
retainedEarnings -65M -57M -52M -49M -34M -29M -23M
accumulatedOtherComprehensiveIncomeLoss 0 -44 000 -26M 0 0 0 0
othertotalStockholdersEquity 61M 60M 59M 33M 34M 33M 33M
totalStockholdersEquity -4M 3M 7M 11M -466 000 5M 10M
totalEquity -4M 3M 7M 11M -466 000 5M 10M
totalLiabilitiesAndStockholdersEquity 14M 19M 23M 27M 3M 10M 13M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 14M 19M 23M 27M 3M 10M 13M
totalInvestments 0 0 0 0 0 0 0
totalDebt 811 000 866 000 937 000 991 000 201 000 194 000 232 000
netDebt -9M -13M -18M -23M -254 000 -7M -10M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol UNCY UNCY UNCY UNCY UNCY UNCY UNCY
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-28 2023-11-14 2023-08-14 2023-05-16 2023-03-31 2022-11-14 2022-08-15
acceptedDate 2024-03-28 16:06:15 2023-11-14 16:20:39 2023-08-14 17:12:17 2023-05-16 08:56:17 2023-03-30 21:24:20 2022-11-14 07:10:23 2022-08-15 17:56:51
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -8M -4M -4M -15M -5M -6M -4M
depreciationAndAmortization 82 000 79 000 78 000 45 000 42 000 40 000 40 000
deferredIncomeTax -287 000 0 0 0 0 0 0
stockBasedCompensation 550 000 929 000 144 000 144 000 197 000 266 000 294 000
changeInWorkingCapital 1M 299 000 -2M 91 000 -1M 2M 255 000
accountsReceivables 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0
accountsPayables 427 000 1M -442 000 -193 000 -641 000 2M 0
otherWorkingCapital 694 000 -1M -1M 193 000 -375 000 -266 000 0
otherNonCashItems 2M -1M -282 000 10M 21 000 0 0
netCashProvidedByOperatingActivities -4M -4M -6M -4M -6M -4M -3M
investmentsInPropertyPlantAndEquipment 0 0 -12 000 0 -2000.000 0 0
acquisitionsNet 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 -12 000 0 -2000.000 0 0
debtRepayment 0 0 0 0 0 0 0
commonStockIssued 0 0 0 -2M 11 000 0 0
commonStockRepurchased 0 10 322M 1 334M 0 0 0 0
dividendsPaid 0 0 0 -192 000 0 0 0
otherFinancingActivites -205 000 -10 322M -1 334M 30M -482 000 0 0
netCashUsedProvidedByFinancingActivities -205 000 -51 000 1 334M 28M -471 000 0 0
effectOfForexChangesOnCash 0 0 6M 0 2000.000 0 0
netChangeInCash -5M -4M -6M 24M -7M -4M -3M
cashAtEndOfPeriod 10M 14M 19M 24M 455 000 7M 11M
cashAtBeginningOfPeriod 14M 19M 24M 455 000 7M 11M 14M
operatingCashFlow -4M -4M -6M -4M -6M -4M -3M
capitalExpenditure 0 0 -12 000 0 -2000.000 0 0
freeCashFlow -4M -4M -6M -4M -6M -4M -3M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-03-28 20:15 ET
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
2024-03-25 11:03 ET
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
2024-03-14 11:03 ET
Unicycive Announces $50 Million Private Placement
2024-03-13 11:03 ET
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
2024-03-07 21:12 ET
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
2024-03-04 12:03 ET
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
2024-02-14 12:03 ET
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
2024-01-29 12:03 ET
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
2024-01-23 12:03 ET
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
2023-12-18 12:03 ET
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
2023-11-29 12:03 ET
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
2023-11-14 21:15 ET
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
2023-10-23 11:03 ET
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
2023-09-06 11:03 ET
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
2023-08-29 11:03 ET
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
2023-08-14 21:36 ET
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
2023-07-21 20:30 ET
CORRECTION FROM SOURCE: 60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
2023-07-21 13:00 ET
60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
2023-07-20 11:03 ET
Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
2023-07-18 11:03 ET
Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
2023-06-29 21:04 ET
Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
2023-06-16 11:38 ET
Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
2023-06-09 13:00 ET
Unicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report®
2023-05-16 12:29 ET
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
2023-04-24 11:00 ET
Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress
2023-03-31 11:00 ET
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
2023-03-07 14:00 ET
The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
2023-03-06 12:00 ET
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
2023-03-03 14:15 ET
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
2023-02-27 12:00 ET
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
2023-02-17 15:35 ET
Unicycive: The Company Developing Key Kidney Therapies
2023-02-06 14:59 ET
Unicycive: This Biotech Company Receives Promising Results From New Trial
2023-02-02 13:30 ET
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
2023-01-23 12:00 ET
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
2023-01-05 12:00 ET
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
2022-12-29 16:31 ET
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
2022-12-28 13:30 ET
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
2022-12-22 12:00 ET
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
2022-12-09 13:00 ET
Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
2022-12-08 13:00 ET
Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive
2022-11-28 12:00 ET
Unicycive to Participate in Upcoming Investor Conferences
2022-11-21 12:00 ET
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
2022-11-14 12:00 ET
Unicycive Announces Third Quarter Financial Results and Provides Business Update
2022-11-10 12:00 ET
Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
2022-11-08 14:00 ET
Unicycive’s Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden
2022-10-26 12:04 ET
Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s Kidney Week 2022
2022-10-12 12:00 ET
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
2022-09-29 11:00 ET
Unicycive Therapeutics to Present at Roth Inaugural Healthcare Opportunities Conference
2022-09-23 13:11 ET
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
2022-09-07 11:00 ET
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)
2022-09-06 11:00 ET
Unicycive Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
2022-08-24 11:00 ET
Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022
2022-08-15 22:03 ET
Unicycive Announces Second Quarter Financial Results and Provides Business Update
2022-07-26 11:00 ET
Unicycive Reports Key Findings from Independent Renal Dietitian Survey
2022-07-20 11:11 ET
Unicycive Reports Key Findings from Market Research with Nephrologists
2022-07-18 11:00 ET
Unicycive Announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets
2022-06-29 16:00 ET
CEO Clip Video Highlights How Unicycive Therapeutics is Working to Improve Quality of Life for Patients Suffering from Kidney Diseases
2022-06-06 12:00 ET
Unicycive to Present at JMP Securities Life Sciences Conference
2022-06-02 12:00 ET
Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia
2022-05-24 12:00 ET
Traders News Source Interviews Dr. Shalabh Gupta, CEO at Unicycive Therapeutics, Inc.
2022-05-12 11:00 ET
Unicycive Announces First Quarter Financial Results and Provides Business Update
2022-04-14 11:10 ET
Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney Diseases
2022-03-31 11:00 ET
Unicycive Announces Full Year 2021 Financial Results and Provides Business Update
2022-03-23 12:30 ET
Unicycive To Ring the Nasdaq Closing Bell on March 29, 2022
2022-03-03 12:00 ET
Unicycive to Present at Upcoming March Investor Conferences
2022-02-02 12:00 ET
Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical Meeting
2022-01-10 12:00 ET
Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
2021-11-29 12:00 ET
Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway
2021-11-11 14:14 ET
Unicycive Therapeutics Announces Third Quarter 2021 Financial Results
2021-10-26 11:30 ET
Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy
2021-09-15 10:17 ET
Unicycive Therapeutics to be Added to Russell Microcap® Index
2021-09-07 10:00 ET
Unicycive Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-08-16 10:00 ET
Unicycive Therapeutics Announces Second Quarter 2021 Financial Results

SEC forms

Show financial reports only

SEC form 8
2024-03-28 17:31 ET
Unicycive Therapeutics, Inc. published news for 2023 q4
SEC form 8
2024-03-28 17:31 ET
Unicycive Therapeutics, Inc. reported for 2023 q4
SEC form 10
2024-03-28 16:06 ET
Unicycive Therapeutics, Inc. reported for 2023 q4
SEC form 10
2024-03-28 00:00 ET
Unicycive Therapeutics, Inc. reported for 2023 q4
SEC form 8
2023-11-14 16:42 ET
Unicycive Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-14 16:20 ET
Unicycive Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-14 00:00 ET
Unicycive Therapeutics, Inc. reported for 2023 q3
SEC form 8
2023-08-15 00:00 ET
Unicycive Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-08-14 21:19 ET
Unicycive Therapeutics, Inc. published news for 2023 q2
SEC form 10
2023-08-14 17:12 ET
Unicycive Therapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Unicycive Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-07-31 16:15 ET
Unicycive Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-07-26 06:05 ET
Unicycive Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-06-29 17:50 ET
Unicycive Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-06-26 16:15 ET
Unicycive Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-05-16 10:30 ET
Unicycive Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-16 08:56 ET
Unicycive Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-05-16 06:05 ET
Unicycive Therapeutics, Inc. published news for 2023 q1
SEC form 8
2023-05-16 00:00 ET
Unicycive Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-16 00:00 ET
Unicycive Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-04-28 16:01 ET
Unicycive Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-04-18 17:25 ET
Unicycive Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-04-10 06:16 ET
Unicycive Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-03-31 07:47 ET
Unicycive Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-31 00:00 ET
Unicycive Therapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-31 00:00 ET
Unicycive Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-30 21:24 ET
Unicycive Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-30 06:16 ET
Unicycive Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-03-06 17:02 ET
Unicycive Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-03-02 06:26 ET
Unicycive Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-02-07 16:10 ET
Unicycive Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-02-02 16:45 ET
Unicycive Therapeutics, Inc. published news for 2022 q4
SEC form 6
2022-12-29 12:55 ET
Unicycive Therapeutics, Inc. published news for 2022 q3
SEC form 6
2022-12-28 09:29 ET
Unicycive Therapeutics, Inc. published news for 2022 q3
SEC form 6
2022-11-14 09:49 ET
Unicycive Therapeutics, Inc. published news for 2022 q3
SEC form 10
2022-11-14 07:10 ET
Unicycive Therapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Unicycive Therapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Unicycive Therapeutics, Inc. published news for 2022 q3
SEC form 6
2022-08-15 18:18 ET
Unicycive Therapeutics, Inc. reported for 2022 q2
SEC form 10
2022-08-15 17:56 ET
Unicycive Therapeutics, Inc. reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Unicycive Therapeutics, Inc. reported for 2022 q2
SEC form 8
2022-08-15 00:00 ET
Unicycive Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-08-08 16:05 ET
Unicycive Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-07-18 16:15 ET
Unicycive Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-06-16 16:15 ET
Unicycive Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-05-12 09:01 ET
Unicycive Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-12 06:09 ET
Unicycive Therapeutics, Inc. reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Unicycive Therapeutics, Inc. reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Unicycive Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-04-19 16:00 ET
Unicycive Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-03-31 11:08 ET
Unicycive Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-31 06:18 ET
Unicycive Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-31 00:00 ET
Unicycive Therapeutics, Inc. published news for 2021 q4
SEC form 8
2022-03-31 00:00 ET
Unicycive Therapeutics, Inc. published news for 2021 q4
SEC form 6
2021-11-29 09:45 ET
Unicycive Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-12 06:36 ET
Unicycive Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-12 00:00 ET
Unicycive Therapeutics, Inc. published news for 2021 q3
SEC form 8
2021-11-12 00:00 ET
Unicycive Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 21:46 ET
Unicycive Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-08-16 09:22 ET
Unicycive Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-16 06:06 ET
Unicycive Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-16 00:00 ET
Unicycive Therapeutics, Inc. published news for 2021 q2
SEC form 8
2021-08-16 00:00 ET
Unicycive Therapeutics, Inc. published news for 2021 q2